Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Serum immunoglobulin G level in patients with lupus nephritis and the effect of treatment with corticosteroids and mycophenolate mofetil.

Yap DY, Yung S, Ma MK, Mok MM, Kwan LP, Chan GC, Chan TM.

Lupus. 2014 Jun;23(7):678-83. doi: 10.1177/0961203314525248. Epub 2014 Feb 19.

PMID:
24554708
2.

A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis.

F L, Y T, X P, L W, H W, Z S, H Z, Z H; MMF in Induction Therapy for Active Lupus Nephritis in Mainland China Study Group.

Lupus. 2008 Jul;17(7):622-9. doi: 10.1177/0961203308089428.

PMID:
18625634
3.

Mycophenolate mofetil versus azathioprine in the maintenance therapy of lupus nephritis.

Sahin GM, Sahin S, Kiziltas S, Masatlioglu S, Oguz F, Ergin H.

Ren Fail. 2008;30(9):865-9. doi: 10.1080/08860220802353843.

PMID:
18925525
4.

Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial.

Ginzler EM, Wax S, Rajeswaran A, Copt S, Hillson J, Ramos E, Singer NG.

Arthritis Res Ther. 2012 Feb 7;14(1):R33. doi: 10.1186/ar3738.

5.

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group.

Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN.

N Engl J Med. 2000 Oct 19;343(16):1156-62.

6.

Mycophenolate mofetil for remission induction in severe lupus nephritis.

Cross J, Dwomoa A, Andrews P, Burns A, Gordon C, Main J, Mathieson P, O'Donoghue D, Jayne D; Renal Association Clinical Trials Subcommittee.

Nephron Clin Pract. 2005;100(3):c92-100. Epub 2005 Apr 11.

PMID:
15824513
7.

Long-term data on corticosteroids and mycophenolate mofetil treatment in lupus nephritis.

Yap DY, Ma MK, Mok MM, Tang CS, Chan TM.

Rheumatology (Oxford). 2013 Mar;52(3):480-6. doi: 10.1093/rheumatology/kes293. Epub 2012 Nov 12.

PMID:
23148090
8.

Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome.

Yap DY, Yu X, Chen XM, Lu F, Chen N, Li XW, Tang CS, Chan TM.

Nephrology (Carlton). 2012 May;17(4):352-7. doi: 10.1111/j.1440-1797.2012.01574.x.

PMID:
22295934
9.

Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis.

Ikeuchi H, Hiromura K, Takahashi S, Mishima K, Sakurai N, Sakairi T, Kaneko Y, Maeshima A, Kuroiwa T, Nojima Y.

Mod Rheumatol. 2014 Jul;24(4):618-25. doi: 10.3109/14397595.2013.844397. Epub 2013 Oct 21.

PMID:
24252014
10.

The effect of mycophenolate mofetil on primary and secondary treatment of primary glomerulonephritis and lupus nephritis.

Paydas S, Kurt C, Taskapan H, Balal M, Sertdemir Y, Pembegul I.

Int Urol Nephrol. 2009;41(1):145-52. doi: 10.1007/s11255-008-9454-4. Epub 2008 Sep 3.

PMID:
18766457
12.

Lupus nephritis: treatment with mycophenolate mofetil.

Kapitsinou PP, Boletis JN, Skopouli FN, Boki KA, Moutsopoulos HM.

Rheumatology (Oxford). 2004 Mar;43(3):377-80. Epub 2004 Jan 6.

PMID:
14963204
13.

Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis.

Lanata CM, Mahmood T, Fine DM, Petri M.

Lupus. 2010 Jul;19(8):935-40. doi: 10.1177/0961203310365714. Epub 2010 Apr 13.

PMID:
20388722
14.

Predictive factors for low rate of remission in a population of Colombian patients with severe proliferative lupus nephritis.

Pinto-Peñaranda LF, Duque-Caballero V, Márquez-Hernández JD, Muñoz-Grajales C, Velásquez-Franco CJ.

Clin Rheumatol. 2015 May;34(5):897-903. doi: 10.1007/s10067-015-2864-7. Epub 2015 Jan 17.

PMID:
25592376
15.

The efficacy of low-dose mycophenolate mofetil for treatment of lupus nephritis in Taiwanese patients with systemic lupus erythematosus.

Weng MY, Weng CT, Liu MF.

Clin Rheumatol. 2010 Jul;29(7):771-5. doi: 10.1007/s10067-010-1403-9. Epub 2010 Mar 2.

PMID:
20195879
16.

Efficacy of enteric-coated mycophenolate sodium in patients with active lupus nephritis.

Mak SK, Lo KY, Lo MW, Chan SF, Tong GM, Wong PN, Wong AK.

Nephrology (Carlton). 2008 Jun;13(4):331-6. doi: 10.1111/j.1440-1797.2007.00862.x.

PMID:
18476916
17.

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.

Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G; LUNAR Investigator Group.

Arthritis Rheum. 2012 Apr;64(4):1215-26. doi: 10.1002/art.34359. Epub 2012 Jan 9.

18.

Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis.

Ong LM, Hooi LS, Lim TO, Goh BL, Ahmad G, Ghazalli R, Teo SM, Wong HS, Tan SY, Shaariah W, Tan CC, Morad Z.

Nephrology (Carlton). 2005 Oct;10(5):504-10.

PMID:
16221103
19.

Treatment for lupus nephritis.

Henderson L, Masson P, Craig JC, Flanc RS, Roberts MA, Strippoli GF, Webster AC.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD002922. doi: 10.1002/14651858.CD002922.pub3. Review.

PMID:
23235592
20.

The safety and efficacy of MMF in lupus nephritis: a pilot study.

Kingdon EJ, McLean AG, Psimenou E, Davenport A, Powis SH, Sweny P, Burns A.

Lupus. 2001;10(9):606-11.

PMID:
11678448

Supplemental Content

Support Center